Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers
Hypertension
About this trial
This is an interventional treatment trial for Hypertension focused on measuring Sodium excretion,, LCZ696
Eligibility Criteria
Inclusion Criteria:
- Patients with heart failure: documented NYHA class II-III heart failure
- Patients with hypertension: stable hypertensive medication for the preceding 2 months
Exclusion Criteria:
- Women of childbearing potential
- History of recent myocardial infarction
- History of dialysis or renal transplant
- Patients with type 1 diabetes mellitus
Sites / Locations
- Novartis Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
LCZ696 to Valsartan - Heart Failure (HF) cohort
Valsartan to LCZ696 - HF Cohort
LCZ696 to Valsartan - Hypertension (HTN) cohort
Valsartan to LCZ696 - HTN cohort
Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.